Molbio Diagnostics IPO Commences Subscription
The initial public offering (IPO) of Molbio Diagnostics opened for subscription on Monday, August 10, with the issue set to close on Wednesday, August 12. The diagnostics firm is offering its shares within a price band of Rs 768-807 apiece. Investors are required to apply for a minimum of 18 equity shares and in multiples thereafter, aiming to raise Rs 940 crore through the offering.
Offer Details and Fund Utilization
The Rs 940 crore IPO comprises a fresh issue of shares worth Rs 200 crore and an Offer For Sale (OFS) of up to 9,166,000 equity shares valued at Rs 740 crore. The net proceeds from the fresh issue are earmarked for funding capital expenditure, specifically for establishing infrastructure for a new research and development facility, acquiring machinery and other equipment, and for general corporate purposes.
Company Profile: A Leader in Molecular Diagnostics
Incorporated in 2000 and based in South Goa, Molbio Diagnostics is a global point-of-care (PoC) molecular diagnostics company. The firm specializes in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for both infectious and non-communicable diseases. Molbio Diagnostics is recognized for its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system.
Financial Performance and Market Valuation
Molbio Diagnostics has demonstrated robust financial growth. For the financial year ended March 31, 2026, the company reported a net profit of Rs 164.14 crore on a revenue of Rs 1,455.17 crore. This follows a net profit of Rs 138.58 crore and a revenue of Rs 1,027.94 crore for the financial year 2024-25. At its current valuations, Molbio Diagnostics commands a market capitalization of approximately Rs 9,300 crore.
Anchor Investor Participation and IPO Allocation
Prior to the public offering, Molbio Diagnostics successfully raised Rs 281.46 crore from 33 anchor investors, allocating 3,487,717 equity shares at Rs 807 apiece. Notable anchor investors included HDFC MF, Goldman Sachs, Kotak MF, International Finance Corporation, and Blackrock Global Funds, among others. The IPO's net offer is allocated as follows: 50 percent for Qualified Institutional Bidders (QIBs), 15 percent for Non-Institutional Investors (NIIs), and 35 percent for retail investors.
Grey Market Premium and Listing Details
Market reports indicated a grey market premium (GMP) of Rs 130 per share for Molbio Diagnostics, suggesting a potential listing gain of approximately 16 percent for investors. Kotak Mahindra Capital Company, IIFL Capital Services, and Jefferies are serving as the book-running lead managers for the IPO, with Kfin Technologies Ltd acting as the registrar. The company's shares are scheduled to be listed on both BSE Ltd and NSE on Monday, August 17.
Analyst Recommendations and Outlook
Several brokerage firms have issued recommendations on the Molbio Diagnostics IPO, largely suggesting a 'subscribe' rating with a long-term investment horizon.
- SBI Securities: Recommended 'Subscribe for long-term,' citing the company's leading position in point-of-care molecular diagnostics, healthy financial performance (CAGR of 31.5% for revenue, 17.2% for EBITDA, and 9.7% for Adjusted PAT over FY24-26), and reasonable valuation relative to its growth profile. They anticipate future growth driven by assay expansion, increased molecular diagnostics adoption, international market penetration, and R&D investments.
- Swastika Investmart: Rated 'Subscribe,' noting Molbio's valuations are in line with industry averages and below the listed peer average P/E. They highlighted the use of fresh issue proceeds for capacity expansion and the company's strong leadership in molecular diagnostics with a scalable device-and-consumables business model.
- BP Equities: Also recommended 'Subscribe,' acknowledging customer concentration risk (84.6% of revenue from government agencies) but emphasizing the differentiated technology platform, recurring revenue model, and high entry barriers supporting its premium positioning.
- Master Capital Services: Advised 'Subscribe for long-term,' pointing to the strong growth potential in molecular diagnostics, driven by PoCT advances and rising demand for early disease detection. They underscored Molbio's strong competitive position, global patent portfolio, and presence in over 90 countries.
- Ventura Securities: Recommended 'Subscribe,' highlighting Molbio's portable Truenat platform and its benefit from the shift towards decentralized and point-of-care testing. They noted strong financial growth and healthy operating margins but flagged high customer concentration as a key risk.